Business Context and Reporting Period
Company: Coeptis Therapeutics Holdings, Inc. (Note: Request metadata listed "Z Squared Inc.", but the filing identifies Coeptis Therapeutics Holdings, Inc.)
Filing Type: Form 8-K (Current Report)
Date of Report: November 1, 2024
Reporting Period: Event-based report regarding agreements entered into on November 1, 2024.
Key Financial Metrics and Agreements
This filing details a Standby Equity Purchase Agreement (SEPA) and a convertible promissory note rather than standard periodic financial results. Key metrics include:
- SEPA Capacity: Up to $20.0 million in Common Stock sales to Yorkville (YA II PN, LTD).
- Convertible Note Principal: $1,304,758 advanced by Yorkville.
- Note Interest Rate: 8% annually (increases to 18% upon default).
- Note Maturity: November 1, 2025.
- Upfront Fees: $25,000 diligence fee (cash) and $200,000 commitment fee ($80,000 in stock, $120,000 deferred).
- Stock Issuance Cap: Yorkville cannot beneficially own more than 4.99% of voting power or exceed 19.99% of outstanding shares (Exchange Cap) without shareholder approval.
Material Changes and Transaction Details
The primary material change is the establishment of a new financing facility:
- SEPA Pricing: Shares sold under the SEPA are priced at 95% of the lowest daily VWAP during the three trading days following the Advance Notice, subject to a minimum acceptable price set by the Company.
- Note Conversion: Yorkville may convert the note into Common Stock at the lower of $1.00 (Fixed Price) or 95% of the lowest daily VWAP over the prior five days (Variable Price), with a floor price of $0.04.
- Investor Notices: Yorkville can trigger share issuances to offset the note balance if the note is outstanding.
- Amortization Events: Mandatory monthly cash payments of $250,000 principal plus a 5% premium and accrued interest are triggered if the daily VWAP falls below the $0.04 floor for five of seven trading days, or if 99% of the Exchange Cap is reached.
Guidance, Outlook, and Risks
Use of Proceeds: The Company expects to use proceeds from the SEPA for working capital and general corporate purposes.
Management Commentary: The Company retains the option to control the timing and amount of share sales under the SEPA, except for Investor Notices triggered by Yorkville.
Risks and Contingencies:
- Dilution: Issuance of shares under the SEPA and note conversion will dilute existing shareholders.
- Amortization Risk: If the stock price remains below the $0.04 floor, the Company faces mandatory cash outflows of $250,000 monthly plus premiums.
- Forward-Looking Statements: The filing includes standard disclaimers that actual results may vary due to market conditions and other uncertainties.
Investor Verification Checklist
- Verify the current trading price of COEP relative to the $1.00 Fixed Price and $0.04 Floor Price to assess conversion and amortization risks.
- Review the exact number of shares issued for the $80,000 commitment fee to calculate immediate dilution.
- Monitor the Company's cash position to determine if it can meet the $250,000 monthly amortization payments if an Amortization Event occurs.
- Check for any subsequent filings regarding the utilization of the $20.0 million SEPA facility.
- Confirm the total outstanding debt balance including the $1,304,758 Yorkville Note.